PYC Therapeutics Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Rohan Hockings

Chief Executive Officer (CEO)

AU$433.2k

Compensación total

Porcentaje del salario del CEO	91.2%
Permanencia del CEO	4.2yrs
Participación del CEO	n/a
Permanencia media de la dirección	4.2yrs
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rohan Hockings en comparación con los beneficios de PYC Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	AU$433k	AU$395k	-AU$38m
Mar 31 2024	n/a	n/a	-AU$30m
Dec 31 2023	n/a	n/a	-AU$22m
Sep 30 2023	n/a	n/a	-AU$22m
Jun 30 2023	AU$438k	AU$395k	-AU$23m
Mar 31 2023	n/a	n/a	-AU$23m
Dec 31 2022	n/a	n/a	-AU$24m
Sep 30 2022	n/a	n/a	-AU$19m
Jun 30 2022	AU$418k	AU$395k	-AU$14m
Mar 31 2022	n/a	n/a	-AU$15m
Dec 31 2021	n/a	n/a	-AU$17m
Sep 30 2021	n/a	n/a	-AU$17m
Jun 30 2021	n/a	n/a	-AU$18m
Mar 31 2021	n/a	n/a	-AU$15m
Dec 31 2020	n/a	n/a	-AU$12m
Sep 30 2020	n/a	n/a	-AU$9m
Jun 30 2020	AU$471k	AU$395k	-AU$7m
Mar 31 2020	n/a	n/a	-AU$6m
Dec 31 2019	n/a	n/a	-AU$5m
Sep 30 2019	n/a	n/a	-AU$5m
Jun 30 2019	AU$482k	AU$395k	-AU$4m
Mar 31 2019	n/a	n/a	-AU$4m
Dec 31 2018	n/a	n/a	-AU$5m
Sep 30 2018	n/a	n/a	-AU$6m
Jun 30 2018	AU$377k	AU$84k	-AU$7m

Compensación vs. Mercado: La compensación total de Rohan($USD289.08K) está por debajo de la media de empresas de tamaño similar en el mercado Australian ($USD776.77K).

Compensación vs. Ingresos: La compensación de Rohan ha sido consistente con los resultados de la empresa en el último año.

CEO

Rohan Hockings (41 yo)

4.2yrs

Permanencia

AU$433,210

Compensación

Dr. Rohan Hockings, MBBS (Hons.), J.D., G.D.L.P, has been Chief Executive Officer at PYC Therapeutics Limited since August 2020. He served as Chief Strategy Officer at PYC Therapeutics Limited until August...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Rohan Hockings	CEO & Executive Director	4.2yrs	AU$433.21k	sin datos
Andrew Taylor	CFO & Company Secretary	2.5yrs	sin datos	sin datos
Kevin Hart	Company Secretary	7.3yrs	AU$165.90k	sin datos

4.2yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de PYC se considera experimentado (3.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rohan Hockings	CEO & Executive Director	5.9yrs	AU$433.21k	sin datos
Michael Rosenblatt	Independent Non-Executive Director	3.6yrs	AU$86.67k	sin datos
David Birch	Member of Ophthalmology Clinical Advisory Board	3.2yrs	sin datos	sin datos
Jason Haddock	Independent Director	3.6yrs	AU$86.67k	sin datos
Alan Tribe	Non-Executive Chair of the Board	6.5yrs	AU$70.00k	34.02% A$ 317.5m
Fred Chen	Member of Scientific Advisory Board & Member of Ophthalmology Clinical Advisory Board	5.1yrs	sin datos	sin datos
Mark Pennesi	Member of Ophthalmology Clinical Advisory Board	3.2yrs	sin datos	sin datos
Jacque Duncan	Member of Ophthalmology Clinical Advisory Board	3.2yrs	sin datos	sin datos

3.6yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de PYC se considera experimentada (4.8 años de antigüedad promedio).

PYC Therapeutics Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Insufficient new directors

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

Recent updates

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Insufficient new directors

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board recently bought AU$81k worth of stock

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy